Abeona Therapeutics Inc.2025财年第一财季实现净利润-12.03百万美元，同比增加61.91%

市场透视2025-05-24

5月24日，Abeona Therapeutics Inc.（ABEO.US）公布财报，公告显示公司2025财年第一财季净利润为-12.03百万美元，同比增加61.91%；其中营业收入为0.00美元，每股基本收益为-0.24美元。从资产负债表来看，Abeona Therapeutics Inc.（ABEO.US）总负债57.97百万美元，其中短期债务8.76百万美元，资产负债比为1.72，流动比率...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2537439153?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-05-24 00:00","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2537439153","market":"us","top_or_hot":-1,"title":"Abeona Therapeutics Inc.2025财年第一财季实现净利润-12.03百万美元，同比增加61.91%","media":"市场透视","content":"<div>\n<p>5月24日，Abeona Therapeutics Inc.（ABEO.US）公布财报，公告显示公司2025财年第一财季净利润为-12.03百万美元，同比增加61.91%；其中营业收入为0.00美元，每股基本收益为-0.24美元。从资产负债表来看，Abeona Therapeutics Inc.（ABEO.US）总负债57.97百万美元，其中短期债务8.76百万美元，资产负债比为1.72，流动比率...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250524000059a489e556&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Abeona Therapeutics Inc.2025财年第一财季实现净利润-12.03百万美元，同比增加61.91%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAbeona Therapeutics Inc.2025财年第一财季实现净利润-12.03百万美元，同比增加61.91%\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-05-24 00:00 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250524000059a489e556&s=b><strong>市场透视</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>5月24日，Abeona Therapeutics Inc.（ABEO.US）公布财报，公告显示公司2025财年第一财季净利润为-12.03百万美元，同比增加61.91%；其中营业收入为0.00美元，每股基本收益为-0.24美元。从资产负债表来看，Abeona Therapeutics Inc.（ABEO.US）总负债57.97百万美元，其中短期债务8.76百万美元，资产负债比为1.72，流动比率...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250524000059a489e556&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LENZ","symbol_name":"Therapeutics","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250524000059a489e556&s=b","article_id":"2537439153","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250524000059a489e556&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2537439153","pubTimestamp":1748016033,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"5月24日，Abeona Therapeutics Inc.公布财报，公告显示公司2025财年第一财季净利润为-12.03百万美元，同比增加61.91%；其中营业收入为0.00美元，每股基本收益为-0.24美元。机构评级：截至2025年5月24日，当前有7家机构对Abeona Therapeutics Inc.目标价做出预测，其中目标均价为19.93美元，其中最低目标价为11.00美元，最高目标价为27.50美元。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":["earning"],"viewcount":null,"language":"zh","relate_stocks":{"LENZ":"Therapeutics","ABEO":"Abeona Therapeutics Inc","ABEOW":"Abeona Therapeutics Inc."},"translate_title":"Abeona Therapeutics Inc. achieved net profit of-12.03 million US dollars in the first fiscal quarter of fiscal year 2025, a year-on-year increase of 61.91%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ABEOW":1,"ABEO":1,"LENZ":1},"content_text":"5月24日，Abeona Therapeutics Inc.（ABEO.US）公布财报，公告显示公司2025财年第一财季净利润为-12.03百万美元，同比增加61.91%；其中营业收入为0.00美元，每股基本收益为-0.24美元。从资产负债表来看，Abeona Therapeutics Inc.（ABEO.US）总负债57.97百万美元，其中短期债务8.76百万美元，资产负债比为1.72，流动比率为4.91。机构评级：截至2025年5月24日，当前有7家机构对Abeona Therapeutics Inc.目标价做出预测，其中目标均价为19.93美元，其中最低目标价为11.00美元，最高目标价为27.50美元。公司简介：Abeona Therapeutics Inc是一家临床阶段的生物制药公司。该公司专注于为危及生命的罕见遗传疾病开发基因疗法和基于血浆的产品。公司临床项目包括pz-cel，这是一种自体工程细胞疗法，目前正在开发用于治疗隐性营养不良大疱性表皮松解症（RDEB）。该公司的开发组合还包括基于腺相关病毒（AAV）的基因疗法，旨在使用该新药治疗医学上需要的未满足的眼科疾病。（以上内容为腾讯自选股基于公开消息，由程序或算法智能生成，仅作为用户看盘参考，不作为投资建议或交易依据。股市有风险，请谨慎决策。）","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2537439153","isCrawlerRequest":true}